Navigation Links
DURECT to Participate in Upcoming Healthcare Conferences
Date:8/21/2012

CUPERTINO, Calif., Aug. 21, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. 

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

  • Matt Hogan, Chief Financial Officer, will present at the Stifel Nicolaus Healthcare Conference on Wednesday, September 5 at 3:15 p.m. Eastern Time.  The conference is being held at the Four Seasons Hotel in Boston.  A live audio webcast of the presentation will be available by accessing http://www.veracast.com/webcasts/stifel/healthcare2012/36113426.cfm
  • James E. Brown, President and CEO, will also present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 10 at 3:40 p.m. Eastern Time.  The conference is being held at the Waldorf Astoria in New York.  A live audio webcast of the presentation will be available by accessing http://www.wsw.com/webcast/rrshq22/drrx.  

A live audio webcast of these presentations will also be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceuticalcompany developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR, SABER, ORADUR®, TRANSDUR®, ELADUR and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
2. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
3. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
4. WAISMANN METHOD® Director Encourages Public to Participate in National Take-Back Day
5. Hill-Rom to Participate in the Deutsche Bank Securities Health Care Conference
6. Hill-Rom to Participate in the Bank of America Merrill Lynch 2012 Health Care Conference
7. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
8. University of Michigans Wolverine Venture Fund Participates in $25 Million Series D Investment in Sonitus Medical
9. BlackStratus participates in Joint FDA-ISPE CGMP Conference
10. ViroPharma To Participate In The JMP Securities Healthcare Conference
11. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... -- http://www.researchandmarkets.com/research/x6mkjm/knee ) has announced the ... by Product Type (Primary (Cemented & Cementless), Partial, ... Japan, Bric, Turkey, Indonesia - Global Analysis and ... --> http://www.researchandmarkets.com/research/x6mkjm/knee ) has announced ... Market by Product Type (Primary (Cemented & Cementless), ...
(Date:2/8/2016)...  Avista Pharma Solutions ("Avista Pharma") announced today that ... Officer (CFO). Mr. Setzer is a finance and operations ... roles within growing technology and life science companies. Prior ... Director of Finance at INC Research, a publicly traded ... . Previously, Mr. Setzer served as CFO of Expression ...
(Date:2/8/2016)... Therapeutics, Inc. announced today that the United States Patent and ... the use of NephroFlow to treat acute kidney injury (AKI). ... "We are pleased to secure our rights to such a ... HemaFlo,s founder, said, "We are pleased to secure our rights ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are pleased ...
Breaking Medicine Technology:
(Date:2/8/2016)... PISCATAWAY, N.J. (PRWEB) , ... February 08, 2016 ... ... of protective footwear and clothing, announced expansion into Canada to provide its range ... has opened a sales office in Quebec City that will provide bilingual customer ...
(Date:2/8/2016)... GA (PRWEB) , ... February ... ... technology and security executive networking and relationship-marketing firm, announced today that nominations ... 2016 Information Security Executive® (ISE®) West Awards. , Awards include the ...
(Date:2/8/2016)... ... 2016 , ... GrassrootsHealth published data from its D*action public ... in the GrassrootsHealth cohort with substantially higher vitamin D levels than a cohort ... states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of vitamin ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... The ... annually in this country. The AutismOne 2016 Conference, which is being held May 25-29 ... often won’t hear elsewhere about helpful interventions and causes of chronic illness in children. ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd ... to his medical and surgical expertise. Technically known as deoxycholic acid or previously ... as a non-surgical alternative for reduction of fat below the chin (aka the ...
Breaking Medicine News(10 mins):